Literature DB >> 15940054

Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts.

Krista G Haanstra1, Ella A Sick, Jan Ringers, Jacqueline A M Wubben, Eva-Maria Kuhn, Louis Boon, Margreet Jonker.   

Abstract

Costimulation blockade as a single immunosuppressive treatment modality is not sufficient to prevent graft rejection. Here, we report an induction therapy using antagonistic antibodies against CD40 and CD86, given twice weekly from day -1 until day 56, followed by a delayed 12-week course of low-dose cyclosporine A (CsA) treatment in the rhesus monkey kidney-allograft model. Low-dose CsA treatment was initiated on day 42 and tapered until total cessation of all treatment on day 126. Treatment with anti-CD40/86 alone resulted in graft survival of 61, 71, 75, 78, and 116 days. Costimulation blockade followed by CsA resulted in more than 3-year drug-free survival in two of four animals. None of the animals developed donor-specific alloantibodies. Transforming growth factor-beta producing cells are present in early as well as in late kidney-graft biopsies and could play a role in the observed long-term drug-free graft survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940054     DOI: 10.1097/01.tp.0000158426.64631.ed

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  19 in total

1.  Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade.

Authors:  Ivana R Ferrer; Maylene E Wagener; Minqing Song; Allan D Kirk; Christian P Larsen; Mandy L Ford
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits.

Authors:  Renaud Snanoudj; Julien Zuber; Christophe Legendre
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

3.  Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques.

Authors:  E K Page; A J Page; J Kwun; A C Gibby; F Leopardi; J B Jenkins; E A Strobert; M Song; R A Hennigar; N Iwakoshi; S J Knechtle
Journal:  Am J Transplant       Date:  2012-07-09       Impact factor: 8.086

4.  Lymphoid-Like Structures with Distinct B Cell Areas in Kidney Allografts are not Predictive for Graft Rejection. A Non-human Primate Study.

Authors:  Margreet Jonker; Jacqueline A M Wubben; Bert A 't Hart; Krista G Haanstra
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 5.  Bidirectional alloreactivity: A proposed microchimerism-based solution to the NIMA paradox.

Authors:  William J Burlingham; Gilles Benichou
Journal:  Chimerism       Date:  2012-04-01

Review 6.  Advances in the immunology of heart transplantation.

Authors:  Joren C Madsen
Journal:  J Heart Lung Transplant       Date:  2017-10-20       Impact factor: 10.247

7.  Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs.

Authors:  H Iwase; B Ekser; V Satyananda; H Zhou; H Hara; P Bajona; M Wijkstrom; J K Bhama; C Long; M Veroux; Y Wang; Y Dai; C Phelps; D Ayares; M B Ezzelarab; D K C Cooper
Journal:  Transpl Immunol       Date:  2015-02-14       Impact factor: 1.708

8.  Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates.

Authors:  I R Badell; P W Thompson; A P Turner; M C Russell; J G Avila; J A Cano; J M Robertson; F V Leopardi; E A Strobert; N N Iwakoshi; K A Reimann; M L Ford; A D Kirk; C P Larsen
Journal:  Am J Transplant       Date:  2011-09-15       Impact factor: 8.086

Review 9.  Memory T-cell-specific therapeutics in organ transplantation.

Authors:  Andrew J Page; Mandy L Ford; Allan D Kirk
Journal:  Curr Opin Organ Transplant       Date:  2009-12       Impact factor: 2.640

10.  Comparative analysis of inflammatory infiltrates in collagen-induced arthritis, kidney graft rejection and delayed-type hypersensitivity in non-human primates.

Authors:  Margreet Jonker; Jacqueline Wubben; Krista Haanstra; Michel Vierboom; Bert 't Hart
Journal:  Inflamm Res       Date:  2012-10-13       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.